Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report

Clin Lymphoma Myeloma. 2009 Aug;9(4):328-30. doi: 10.3816/CLM.2009.n.065.

Abstract

Multiple myeloma patients with plasmablastic morphology of tumor cells and extramedullary presentation of disease often have an aggressive clinical course and resistance to chemotherapy. We describe a case of an elderly patient who presented with extramedullary, IgA-lambda-secreting multiple myeloma with plasmablastic features who demonstrated impressive clinical response to single-agent lenalidomide. This is the first description of a plasmablastic variety of multiple myeloma successfully treated with lenalidomide alone.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Lenalidomide
  • Male
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology*
  • Plasma Cells / drug effects
  • Plasma Cells / pathology*
  • Remission Induction
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use

Substances

  • Antineoplastic Agents
  • Thalidomide
  • Lenalidomide